Contrasting Nephros (NASDAQ:NEPH) and Sintx Technologies (NASDAQ:SINT)

Sintx Technologies (NASDAQ:SINT) and Nephros (NASDAQ:NEPH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Profitability

This table compares Sintx Technologies and Nephros’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sintx Technologies	-358.79%	-140.68%	-78.29%
Nephros	-6.86%	-11.39%	-8.30%

Risk & Volatility

Sintx Technologies has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500. Comparatively, Nephros has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500.

Institutional & Insider Ownership

18.4% of Sintx Technologies shares are held by institutional investors. Comparatively, 41.1% of Nephros shares are held by institutional investors. 0.0% of Sintx Technologies shares are held by company insiders. Comparatively, 4.1% of Nephros shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Sintx Technologies and Nephros”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sintx Technologies	$2.63 million	1.44	-$8.26 million	($50.56)	-0.06
Nephros	$14.24 million	1.13	-$1.58 million	($0.09)	-16.89

Nephros has higher revenue and earnings than Sintx Technologies. Nephros is trading at a lower price-to-earnings ratio than Sintx Technologies, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Sintx Technologies and Nephros, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sintx Technologies	0	0	0	0	0.00
Nephros	0	0	1	0	3.00

Nephros has a consensus price target of $5.00, indicating a potential upside of 228.95%. Given Nephros’ stronger consensus rating and higher probable upside, analysts clearly believe Nephros is more favorable than Sintx Technologies.

Summary

Nephros beats Sintx Technologies on 11 of the 13 factors compared between the two stocks.

About Sintx Technologies

Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.

About Nephros

Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.